Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06190249 |
| Title | Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma |
| Recruitment | Suspended |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | James Isaacs, MD |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |